Charles River Laboratories International Inc (CRL)
195.77
+1.58
(+0.81%)
USD |
NYSE |
Nov 22, 16:00
195.80
+0.03
(+0.02%)
After-Hours: 20:00
Charles River Laboratories International Enterprise Value: 12.17B for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 12.17B |
| November 21, 2024 | 12.09B |
| November 20, 2024 | 11.77B |
| November 19, 2024 | 11.68B |
| November 18, 2024 | 11.75B |
| November 15, 2024 | 11.76B |
| November 14, 2024 | 12.23B |
| November 13, 2024 | 12.72B |
| November 12, 2024 | 13.20B |
| November 11, 2024 | 13.45B |
| November 08, 2024 | 13.18B |
| November 07, 2024 | 12.92B |
| November 06, 2024 | 13.12B |
| November 05, 2024 | 11.81B |
| November 04, 2024 | 11.49B |
| November 01, 2024 | 11.42B |
| October 31, 2024 | 11.29B |
| October 30, 2024 | 11.44B |
| October 29, 2024 | 11.57B |
| October 28, 2024 | 11.70B |
| October 25, 2024 | 11.47B |
| October 24, 2024 | 11.51B |
| October 23, 2024 | 11.71B |
| October 22, 2024 | 11.67B |
| October 21, 2024 | 12.14B |
| Date | Value |
|---|---|
| October 18, 2024 | 12.27B |
| October 17, 2024 | 12.28B |
| October 16, 2024 | 12.14B |
| October 15, 2024 | 12.08B |
| October 14, 2024 | 12.04B |
| October 11, 2024 | 12.03B |
| October 10, 2024 | 11.95B |
| October 09, 2024 | 11.76B |
| October 08, 2024 | 11.72B |
| October 07, 2024 | 11.84B |
| October 04, 2024 | 11.92B |
| October 03, 2024 | 11.86B |
| October 02, 2024 | 12.03B |
| October 01, 2024 | 12.09B |
| September 30, 2024 | 12.23B |
| September 27, 2024 | 12.52B |
| September 26, 2024 | 12.52B |
| September 25, 2024 | 12.24B |
| September 24, 2024 | 12.64B |
| September 23, 2024 | 12.80B |
| September 20, 2024 | 12.91B |
| September 19, 2024 | 13.10B |
| September 18, 2024 | 12.92B |
| September 17, 2024 | 12.93B |
| September 16, 2024 | 12.80B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.545B
Minimum
Mar 18 2020
25.61B
Maximum
Sep 24 2021
14.51B
Average
13.62B
Median
Dec 31 2022
Enterprise Value Benchmarks
| Boston Scientific Corp | 141.27B |
| CVS Health Corp | 129.02B |
| Arbutus Biopharma Corp | 537.32M |
| FibroBiologics Inc | 82.40M |
| Biomarin Pharmaceutical Inc | 11.91B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 68.68M |
| Revenue (Quarterly) | 1.010B |
| Total Expenses (Quarterly) | 892.36M |
| EPS Diluted (Quarterly) | 1.33 |
| Gross Profit Margin (Quarterly) | 34.56% |
| Profit Margin (Quarterly) | 6.80% |
| Earnings Yield | 4.09% |
| Operating Earnings Yield | 5.22% |
| Normalized Earnings Yield | 4.092 |